Passport Health, in partnership with vaccine manufacturer PaxVax, Inc. is participating in a clinical study to test the effects of the oral typhoid vaccination, Vivotif® (Typhoid Vaccine Live Oral Ty21a). The study will look at the side effects that could occur when taking Vivotif across the range of approved potencies. The study is part of a post-marketing commitment to the U.S. Food and Drug Administration.
Participants will be required to keep a 21-day log of any potential side effects they may feel from the vaccine. For their time, Passport Health will provide to participants a free Vivotif vaccination as well as stipend for completing the study. Those eligible to participate are Passport Health clients within the following areas: Baltimore, MD, San Diego, CA, and Tustin, CA.
"This is a unique opportunity for both Passport Health and our clients," said Melanie French, Vice President of Clinic Operations for Passport Health. "Our clients will be able to give feedback directly to PaxVax on this vaccine. Our nurses often help individuals with any feedback they may have, but being able to give it directly to the manufacturer is something that will help both PaxVax and future travel clients."
The study will last from August 2015 to approximately August 2016 and will involve approximately 950 participants located within the three regions listed above.